Cantor Fitzgerald raised the firm’s price target on Reata Pharmaceuticals to $138 from $121 and keeps an Overweight rating on the shares. The price target increase is not only a by product of the firm’s incremental "housekeeping" adjustments to U.S. and E.U. SKYCLARYS revenue projections, but also reflects optimism for SKYCLARYS to usher in a paradigm shift in the standard-of-care for Friedreich Ataxia patients in the E.U., as well as the U.S., the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RETA:
- Reata Pharmaceuticals price target raised to $75 from $35 at SVB Securities
- Reata Pharmaceuticals price target raised to $105 from $75 at Stifel
- Reata Skyrockets on FDA Approval for Friedreich’s Ataxia Drug
- Reata Pharmaceuticals price target raised to $85 from $40 at Baird
- Reata Pharmaceuticals price target raised to $121 from $61 at Cantor Fitzgerald
